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Background: Adenocarcinomas of both the gastroesophageal junction and stomach are molecularly complex, but
differ with respect to epidemiology, etiology and survival. There are few data directly comparing the frequencies of
single nucleotide mutations in cancer-related genes between the two sites. Sequencing of targeted gene panels
may be useful in uncovering multiple genomic aberrations using a single test.
Methods: DNA from 92 gastroesophageal junction and 75 gastric adenocarcinoma resection specimens was
extracted from formalin-fixed paraffin-embedded tissue. Targeted deep sequencing of 46 cancer-related genes was
performed through emulsion PCR followed by semiconductor-based sequencing. Gastroesophageal junction and
gastric carcinomas were contrasted with respect to mutational profiles, immunohistochemistry and in situ
hybridization, as well as corresponding clinicopathologic data.
Results: Gastroesophageal junction carcinomas were associated with younger age, more frequent intestinal-type
histology, more frequent p53 overexpression, and worse disease-free survival on multivariable analysis. Among all
cases, 145 mutations were detected in 31 genes. TP53 mutations were the most common abnormality detected,
and were more common in gastroesophageal junction carcinomas (42% vs. 27%, p = 0.036). Mutations in the Wnt
pathway components APC and CTNNB1 were more common among gastric carcinomas (16% vs. 3%, p = 0.006), and
gastric carcinomas were more likely to have ≥3 driver mutations detected (11% vs. 2%, p = 0.044). Twenty percent
of cases had potentially actionable mutations identified. R132H and R132C missense mutations in the IDH1 gene
were observed, and are the first reported mutations of their kind in gastric carcinoma.
Conclusions: Panel sequencing of routine pathology material can yield mutational information on several driver
genes, including some for which targeted therapies are available. Differing rates of mutations and clinicopathologic
differences support a distinction between adenocarcinomas that arise in the gastroesophageal junction and those
that arise in the stomach proper.
Keywords: Gastric cancer, Gastroesophageal junction cancer, Gastric cancer genomics, Gastric cancer sequencing* Correspondence: hlichang@bccrc.ca
1University of British Columbia, Vancouver, Canada
2Division of Anatomic Pathology, Department of Pathology and Laboratory
Medicine, Vancouver General Hospital, 855 12 Ave W, Vancouver, BC V5Z 1 M9,
Canada
Full list of author information is available at the end of the article
© 2015 Li-Chang et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Li-Chang et al. BMC Cancer  (2015) 15:32 Page 2 of 12Background
Gastric cancer accounts for over 10,000 deaths annually
in the United States [1], and is the second most com-
mon cause of cancer mortality worldwide [2]. Although
carcinomas of the gastroesophageal junction (GEJ) have
been grouped with gastric carcinomas in cancer regis-
tries and in clinical trials for targeted therapies [3], le-
sions at these two sites have distinct clinical features.
Adenocarcinomas of the stomach proper are primarily
caused by Helicobacter pylori infection [4] and are de-
creasing in incidence worldwide [1]. In contrast, GEJ
cancers are most associated with gastroesophageal reflux
disease [2-5] and obesity [6], and the incidence of GEJ car-
cinomas has remained stable over the past 20 years [7]. In
addition, the prognosis of GEJ carcinomas has been noted
to be worse than gastric carcinomas, and there is uncer-
tainty as to whether GEJ carcinomas should be staged as
gastric or esophageal tumors [8]. Recognizing the distinc-
tion between carcinomas of the GEJ, esophagus, and
stomach may enhance the collection of meaningful epide-
miologic data and result in increased management preci-
sion [9].
Several studies have noted differences in the molecular
characteristics of GEJ carcinomas versus those that arise
elsewhere in the stomach. TP53 mutations are more fre-
quent in the GEJ than in the distal stomach, while loss of
heterozygosity of the TP53 locus is also more common in
GEJ tumors [10,11]. Significant differences in promoter
methylation rates of APC and CDKN2A have also been
described [12]. Furthermore, differences in APC mutation
rates and protein expression, as well as differences in glo-
bal gene expression profiles between the two sites have
also been demonstrated [13-16].
Testing of amplifications of the ERBB2 (also known as
HER2) gene in gastric and gastroesophageal junction can-
cers is now routine practice in many institutions [17].
Similarly, testing for driver mutations, particularly single
nucleotide substitutions, in oncogenes and tumour sup-
pressor genes currently informs treatment in adenocarcin-
omas of other sites such as the lung and colon [18-20]. As
further molecular targets are discovered across disease
sites, effective assays will be required to determine can-
cers’ susceptibility to targeted treatment.
Next-generation sequencing may be used in the near
future to interrogate multiple genes in a single sample,
and these data could be used to inform clinicians of driver
mutations and guide targeted treatment. Targeted panel
sequencing is a form of next-generation sequencing where
single nucleotide variants are detected in a limited
number of previously determined genomic loci, which
by intention are often prognostically and therapeutically
critical. Panel sequencing enables multiplexing of sam-
ples, and deep coverage (>500x) facilitates the analysis
of suboptimal template material from archival tissueand samples with low tumor cellularity. The narrower set
of genes also allows for quicker specimen processing and
bioinformatic analysis. Thus, actionable results can be ob-
tained within days, rather than the weeks, compared to
whole genome and exome approaches. However, data is
restricted by the inherently biased selection of genes, and
the inability to detect copy number changes, loss of het-
erozygosity, and structural rearrangements such as gene
fusions. Thus, the effective use of NGS requires careful as-
sessment of technologies, assay limitations, template re-
quirements, and the research and clinical questions under
consideration.
The objectives of this study were to probe the utility of
panel sequencing on formalin-fixed paraffin-embedded
(FFPE) tissue, and to compare clinically annotated GEJ
and gastric carcinomas through panel sequencing of the
hotspots of 46 cancer genes. We also sought to compare
the frequencies of mutations identified with panel sequen-
cing of hotspots against whole-exome sequencing, using
publically available data from The Cancer Genome Atlas.
Methods
Case selection and retrieval of clinicopathologic data
Institutional ethics approval was obtained from the
University of British Columbia/British Columbia Cancer
Agency research ethics board (#H07-2807), and research
was conducted in accordance with the Helsinki declar-
ation. Cases of gastric carcinoma were retrieved from de-
partmental archives from the British Columbia Cancer
Agency (BCCA), a provincial referral center. Inclusion cri-
teria were referral to the agency between 2004 and 2010,
available FFPE tissue from surgical resection of the pri-
mary tumor, complete clinicopathologic data including
clinical outcomes on follow-up, and the absence of meta-
static disease at presentation. Biopsy specimens of primary
and metastatic lesions were excluded due to the absence
of complete pathologic data. GEJ location was defined as
lesions with an epicenter within 5 cm of the proximal end
of the gastric rugal folds [21]. No distinction was made be-
tween tumors with regards to the location of their epicen-
ter within the 5 cm of the GEJ (i.e. Siewert type was not
recorded) [22]. Carcinomas located exclusively within the
esophagus were excluded, as per the most recent WHO
criteria [21]. All gastric tumors located distal to the GEJ
were binned together for this study. Clinicopathologic
data was collected retrospectively through review of pa-
tients’ charts by a member of the clinical team, as well as
through review of pathology reports.
Tissue microarray construction, immunohistochemistry
and in situ hybridization
Tissue microarray construction was carried out using
two 0.6 mm cores from two separate sections of tumor.
Immunohistochemical staining for p53 (1:100; clone
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(1:75; Sigma-Aldrich, St. Louis, MO), and the mismatch
repair (MMR) proteins including hMLH1 (1:25; clone
ES05, Leica, Wetzlar, Germany), MSH2 (1:5; clone 25D12,
Leica), hMSH6 (1:300; clone PU29, Leica), and hPMS2
(1:150; clone MOR4G, Leica) was performed on the XT
platform (Ventana). Expression of p53 was scored as
absent (<1% nuclear staining), normal (1-60% nuclear
staining of any intensity), or overexpression (>60% nuclear
staining of any intensity). Baf250a and MMR proteins were
scored as intact (≥1% staining) or negative (<1% staining)
based on protein expression specifically in tumour cells
(i.e. immune and stromal expression was ignored). ERBB2
silver in situ hybridization (SISH) was performed using
the XT automatic IHC/ISH staining platform (Ventana). A
ERBB2:CEP17 ratio <2.0 was classified as non-amplified,
and a value ≥2.0 as amplified. Enumeration of SISH sig-
nals was based on established protocols [17].
DNA sample processing, sequencing, and variant calling
In each case, hematoxylin and eosin slides were used to
guide macrodissection or scrolling of tumor tissue from
FFPE slides following outlining of tumours by an ana-
tomical pathologist. Tumor DNA from each case was ex-
tracted using Qiagen FFPE DNA extraction kit (Qiagen,
Venlo, Netherlands); no germline DNA was extracted. Ex-
tracted DNA was quantified using the QUBIT HS dsDNA
assay (Life Technologies Gaithersburg, MD, USA); all
cases had a minimum of 10 ng of DNA extracted from
FFPE, in keeping with a previously reported requirement
for the assay [21]. A minimum A260/280 ratio of 1.8 was
required for each DNA sample. DNA amplicon library
construction was performed using DNA primers from the
Ion Ampliseq™ Cancer Hotspot Panel v1 (Life Technologies).
The kit consists of 207 primer pairs that cover 739 hotspots
within 46 cancer-related genes (Additional file 1: Table S1).
Indexed amplicon libraries were pooled for emulsion poly-
merase chain reaction and sequencing on the Ion Torrent
PGM platform (Life Technologies). A minimum of at least
500x base pair coverage was required for each case. Vari-
ant calling was performed using the Torrent Variant Caller
v2.2 (Life Technologies) using the hg19 reference genome.
Only variants present at frequencies ≥5% were considered.
Because germline DNA was unavailable for comparison,
variants were excluded as possible somatic mutations if
they were identified as single nucleotide polymorphisms
with mean allele frequencies of >0 within the dbSNP data-
base (www.ncbi.nlm.nih.gov/SNP); their status as non-
germline variants was further confirmed using a PubMed
search (www.ncbi.nlm.nih.gov/pubmed).
Comparison with the Cancer Genome Atlas (TCGA) data
Curated somatic mutation calls for 281 TCGA stomach
adenocarcinoma samples with known anatomical siteswere retrieved from the TCGA Data Portal (https://tcga-
data.nci.nih.gov/tcga/) on February 19, 2014. Protein-coding
mutations located in the regions amplified by the Ion
Ampliseq™ Cancer Hotspot Panel v1 in each of the 46
genes were obtained for cases and stratified by location
(60 cardia/proximal and gastroesophageal junction versus
221 fundus/body, antrum/distal and stomach NOS). Copy
number data, RNA expression data, and protein expres-
sion data were not considered as our own assay only de-
tects single nucleotide variants (SNVs) and small basepair
insertions/deletions (INDELs). The frequencies of muta-
tions, irrespective of the type of mutation, were compared
versus the hotspot multiple panel sequencing that we
performed.
Data analysis
Mann–Whitney U-tests and student t-tests were used to
compare linear variables, where appropriate. Fisher exact
and chi-square tests, where appropriate, were used to com-
pare categorical values. Survival analyses were performed
using log-rank (Kaplan-Meier) and Cox proportional haz-
ards tests. The 46 panel genes were mapped to the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [22,23] and
the Ingenuity® Integrated Pathway Analysis program
(Qiagen) to identify oncogenic pathways and networks
enriched for mutations, and to test for statistically signifi-
cant differences between gastroesophageal junction and
gastric adenocarcinoma specimens. P values were cor-
rected for multiple testing using the Benjamini–Hochberg
(BH) correction [24]. All statistical tests were two-tailed
and a P value of < .05 was considered statistically signifi-
cant. Statistical analyses were performed using SPSS
Statistics software (v22, IBM, Armonk, NJ, USA) and the
R statistical language v.2.15.1 (R Core Team (2012). R: A
language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria.
ISBN 3-900051-07-0, URL http://www.R-project.org/).
Results
Within departmental archives at the BCCA, 229 resection
specimens of gastric and GEJ carcinomas were obtained
from 2004 to 2010 and were available for construction of
a tissue microarray. DNA was available for extraction for
176 cases. No clinicopathologic data was available for cor-
relation in 6 cases. Three cases had metastatic disease
documented within a month of presentation, and these
were excluded from the analysis. Of the remaining 167
cases, 92 originated in the gastroesophageal junction and
75 originated in the remainder of the stomach (Figure 1).
Clinicopathologic differences between GEJ and gastric
carcinomas
The clinicopathologic features of these cases are summa-
rized in Table 1 and anonymized clinical data is provided
Figure 1 Flow diagram detailing case selection and exclusion for the study cohort.
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carcinomas were associated with younger age at resec-
tion, more frequent intestinal-type and less frequent dif-
fuse histology, more frequent p53 overexpression and
less frequent loss of p53 expression, more frequent stage
III disease, less frequent stage I disease, and more fre-
quent recurrences. Disease-free survival was significantly
worse among patients with GEJ carcinomas (Figure 2A),
though the two cohorts were not statistically different in
terms of overall survival (Figure 2B). Other clinicopatho-
logic features were similar between tumors of the two lo-
cations, including T-stage, resection margin involvement,
ERBB2 amplification, and MMR protein loss (Table 1).
The proportion of diffuse carcinomas in the Lauren classi-
fication) was similar between the two sites. Subgroup
analysis of only intestinal-type carcinomas showed per-
sistent differences between GEJ and gastric carcinomas in
disease-free survival and p53 expression. Differences in
age, p53 expression and outcome persisted when consid-
ering only intestinal-type carcinomas, as well as when
tumours were stratified into three subtypes (proximal non-
diffuse, diffuse, and distal non-diffuse) as suggested by
Shah et al. [16] (Additional file 3: Table S3).
On multivariable analysis, GEJ location was independ-
ently associated with worse disease-free survival (Cox
Proportional Hazard =2.08 [95% confidence interval:
1.25-3.44], p = 0.005) along with margin status and micro-
satellite instability (Additional file 4: Table S4). Age, tumor
grade and margin involvement were independently prog-
nostic of overall survival (Additional file 5: Table S5).Mutations identified with the cancer panel
Among all cases, 145 mutations were detected in 31 genes,
with 75 mutations detected among 57 of the tumors from
the GEJ, and 70 mutations detected among 43 gastric tu-
mors (Figure 3). No mutations were detected in 35 (38%)
and 32 (43%) of the tumors from the GEJ and stomach, re-
spectively. TP53 was the most commonly mutated genes,
with variants identified in 59 of 167 cases (35%). The next
most commonly mutated genes were PI3KCA (6%),
CTNNB1 (5%), KRAS (5%) and SMAD4 (4%). Other vari-
ants included hotspot mutations in IDH1 (2 cases), JAK3
(3 cases), and FLT3 (2 cases). A single mutation was iden-
tified in 70 cases (42%), 2 mutations were identified in
20 cases (12%), and ≥3 mutations were identified in
10 cases (6%).
No mutations were identified within the hotspot regions
of ALK, CSF1R, EGFR, FGFR2, HNF1A, HRAS, JAK2,
MPL, NPM1, NRAS, SRC, STK11 or VHL. All variant calls
are available in the supplementary data (Additional file 6:
Table S6).
Differences in mutations between the GEJ and stomach
TP53 mutations were identified in 39 of 92 (42%) of GEJ
tumors, and in 20 of 75 (27%) gastric tumors (p = 0.036).
When subdivided into the 3 subtypes suggested by Shah
et al. [16], TP53 mutations occurred more frequently in
proximal nondiffuse cancers (44%) than in diffuse cancers
(37%) and distal nondiffuse cancers (20%; p = 0.024). This
classification also showed more frequent mutations in
KRAS within distal nondiffuse cancers (12%) versus
Table 1 Summary of the clinocopathologic variables in the cohort’s clinicopathologic variables within cardia and
non-cardia adenocarcinomas
Clinicopathologic variable Gastroesophageal junction (n = 92) Non-cardia (n = 75) Overall (n = 167) p
Age (mean, years) 61.5 +/- 9.6 [33-80] 66.3 +/- 11.9 [33-84] 63.7 +/- 10.9 [33-84] 0.001
Sex 0.297
Male 70 (76) 51 (68) 121 (73)
Female 22 (24) 24 (32) 46 (27)
Histologic subtype (Lauren) 0.008
Intestinal 65 (71) 36 (48) 101 (60)
Diffuse 15 (16) 26 (35) 41 (25)
Mixed 12 (13) 13 (17) 25 (15)
Stage (AJCC) 0.031
IA-B 10 (11) 19 (25) 29 (17)
IIA-B 60 (65) 45 (60) 105 (63)
III-A-C 22 (24) 11 (15) 33 (20)
Grade 0.415
Well differentiated (G1) 4 (5) 10 (6)
Moderately differentiated (G2) 39 (42) 25 (33) 64 (38)
Poorly differentiated (G3) 47 (51) 46 (61) 93 (56)
Resection margin 0.306
Uninvolved 74 (80) 65 (87) 139 (83)
Involved 18 (20) 10 (13) 28 (17)
ERBB2 amplification 0.654
Absent 78 (85) 66 (88) 144 (86)
Present 14 (15) 9 (12) 23 (14)
BAF250a (ARID1A) expression 0.111
Intact 73 (79) 51 (68) 124 (74)
Absent 19 (21) 24 (32) 43 (26)
p53 expression 2.8x10-4
0 – absent 32 (35) 47 (63) 79 (47)
1 – normal (1-60%) 17 (19) 14 (19) 31 (19)
2 - increased (>60%) 43 (47) 14 (19) 57 (34)
Mismatch repair proteins 0.244
Intact 77 (84) 57 (76) 135 (80)
Abnormal 15 (16) 18 (24) 33 (20)
Number of recurrences 57 (62) 32 (43) 89 (53) 0.019
Median progression-free survival (Months) 12 18 15
Number of deaths 69 (75) 48 (64) 117 (70) 0.130
Median overall survival (Months) 18.0 23.0 20.0
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(p = 0.12). No significant differences in mutation frequen-
cies were present among the other individual genes in the
panel. Two components of the Wnt pathway, APC and
CTNNB1, were in aggregate mutated more frequently
in gastric carcinomas than in GEJ tumors (16% vs. 3%,
p = 0.006). Gastric carcinomas more frequently had muta-
tions in 3 or more genes (11% vs. 2%, p = 0.044; Figure 4).No differences in the involvement of oncogenic pathways
were noted between the two sites, based on mutational
profiles.
Potentially actionable mutations
Targeted therapies are available or in development for
mutations occurring in the following genes: AKT [25],
BRAF [26], ERBB2 [27], ERBB4 [28], FGFR1 [29], FGFR3
Figure 2 Comparison of disease-free survival and overall survival between patients with gastroesophageal and gastric carcinomas.
A) Disease free survival was significantly worse for gastroesophageal carcinomas (solid lines) compared to gastric carcinoms (dotted lines),
Log-rank test; p = 0.002, though B) overall survival did not differ between the two disease sites (Log-rank test; p = 0.225).
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KRAS [36], MET [34], PDGFRA [37], PIK3CA [25], PTEN
[25], PTPN11 [38], RET [39], SMO [40]. Mutations in
these genes were identified in 32 cases (19%), including 6
cases (4%) with 2 mutations and 3 cases (2%) with ≥3 mu-
tations. The distribution of actionable mutations was notsignificantly different between GEJ and gastric carcinomas
(p = 0.327; Figure 4).
Prognostic significance of mutations
ERBB4 mutations were associated with worse disease-
free survival (p = 0.018), while there was a trend towards
Figure 3 Somatic mutations identified in gastroesophageal junction and gastric carcinomas. TP53 mutations were identified in a larger
proportion of gastroesophageal junction tumors, while abnormalities in APC/CTNNB1 occurred more frequently in gastric tumors. Black blocks
represent truncating mutations, while grey blocks represent missense mutations. Cases and genes in which mutations were not identified are
not included.
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ABL1 (p = 0.063) and JAK3 (p = 0.059). None of these
mutations were prognostically significant after accounting
for age, sex, Lauren subtype, stage, grade and margin
status. Mutations in BRAF (p < 0.001), FGFR3 (p < 0.001),
FLT3 (p < 0.001) were associated with worse overall survivalFigure 4 Proportions of GEJ and gastric carcinomas with
numbers of identified total and actionable mutations. Solid dark
areas in the columns represent cases with 1 mutation, dark diagonal
lined areas represent cases with 2 mutations, and spotted areas
represent cases with 3 or more mutations.on univariate analysis as a result of a single case with
mutations in all three of these genes.). BRAF mutation
remained prognostically significant after accounting for
age, sex, Lauren subtype, stage, grade and margin status
(p = 0.002).
Comparison with TCGA data
When assessing the hotspot regions covered by the se-
quencing panel, the overall number of mutated genes per
case was similar between the TCGA and study cohorts
(p = 0.659), including when comparing either GEJ (p =
0.399) or gastric (p = 0.845) tumors only (Figure 5A). A
trend towards more frequent cases with mutations in ≥3
genes in the stomach compared to the GEJ was also ob-
served in the TCGA data (12% vs. 3%, p = 0.054). The
overall frequency of TP53 mutations was not different be-
tween the study cohort and the TCGA cohort (p = 0.230).
No differences in TP53, KRAS, and APC/CTNNB1 muta-
tion rates between GEJ and gastric carcinomas were ob-
served in the TCGA dataset (Figures 5B-D). The mutated
genes in the TCGA data set are included in Additional
file 7: Table S7. Regarding the mutations with possible
prognostic significance identified in our cohort, there was
a trend towards worse overall survival associated with
BRAF mutations (p = 0.079), while no prognostic associ-
ation was found in the TCGA cohort in association with
mutations in ERBB4, ABL1, JAK3, FLT3 or FGFR3.
Figure 5 Comparison of the frequency of mutations within hotspots identified in the study cohort using panel sequencing, compared
to mutations identified using whole exome sequencing in the TCGA data. A) Mutations across mutational hotspots in the 46 genes in the
panel, B) mutations in TP53, C) mutations in KRAS, and D) mutations in the Wnt signaling components APC and CTNNB1.
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This study aimed to probe the utility of panel sequen-
cing in identifying single nucleotide changes in routinely
processed gastric resection specimens, which could be
used to guide targeted therapies. We secondarily sought
to contrast GEJ and gastric carcinomas through targeted
deep sequencing of a panel of 46 cancer-related genes,
which revealed some differences at the genomic level that
may reflect differing clinicopathologic profiles. Finally, we
also sought to compare the frequencies of mutations ob-
tained using this panel with results from whole exome se-
quencing in The Cancer Genome Atlas.
Adenocarcinomas of the gastrointestinal tract are mo-
lecularly heterogeneous and complex [41-44]. In gastric
carcinoma, deep sequencing of single nucleotide poly-
morphism and RNA expression arrays have recently re-
vealed abnormalities in several pathways including WNT,
Hedgehog, cell cycling, DNA damage repair and the
epithelial-to-mesenchymal transition [45]. The current
use of multiple single gene tests is untenable given thiscomplexity, particularly in the presence of a growing num-
ber of targeted therapies, constrained resources, and lim-
ited tissue availability. Thus, it is desirable to investigate
multiple genes simultaneously. Panel sequencing has a
sensitivity of close to 100% relative to conventional assays
such as Sanger sequencing and PCR-based methods, as
well as an ability to detect SNVs and INDELs at allele fre-
quencies as low as 5% and 20%, respectively, in both FFPE
[21,46-48] and cytology specimens [49-52]. Targeted panel
sequencing can detect aberrations in cancer-related genes
in early gastric cancers and precursors lesions [53], and its
deep coverage could be particularly useful in gastric can-
cer by providing adequate results despite scant biopsy ma-
terial and the admixture of tumor cells with desmoplasia
and inflammatory cells.
Putative driver mutations were identified in a majority
of GEJ and gastric carcinomas investigated in this study.
By far the most frequently detected mutated gene was
TP53, and these mutations have also been detected in
early stage and precursor lesions using the same assay
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cases, reinforcing the idea that multiple genes need to be
interrogated at once in genomically complex tumors such
as gastric adenocarcinomas. A case with a mutation in
BRAF (as well as FLT3 and FGFR3) was associated with
poor overall survival on both univariate and multivari-
able analysis. This finding mirrors a trend observed in
the TCGA data towards poor overall survival in BRAF-
mutated tumours, suggesting that in some cases panel se-
quencing could have a prognostic role.
We were also able to detect potentially actionable mu-
tations in approximately 20% of cases, which involved ei-
ther genes or pathways where targeted therapies are
available or in development. While this number would
ideally be higher, our assay only covered certain hotspot
regions of these genes, and did not account for copy
number alterations that could also yield useful informa-
tion. Further refinement of such panels to include a
broader range of genes and gene segments will likely
increase the proportion of cases in which mutations
are identified. For example, although TP53 mutations
occur throughout the gene, the panel primarily covers
exons 5–8, and some of the gene segments that were
not sequenced are more frequently associated with
loss of p53 on immunohistochemistry [54]. This fact
may potentially explain both the differences in the rates
of TP53 mutations and patterns of immunohistochemi-
cal expression observed in the GEJ and stomach. Never-
theless, this study does demonstrate that single nucleotide
variants can be identified from routine/archival path-
ology materials, and that with additional refinement
panel sequencing may have a significant role in the
future.
An unexpected result of the cancer hotspot panel se-
quencing approach was the identification of mutations
in genes usually associated with non-epithelial malignan-
cies, such as IDH1 R132H/R132C, JAK3 V722I, and
FLT3 A680V. The IDH1 variants identified occur pri-
marily in glial and hematologic malignancies, and result
in altered cancer cell metabolism [55]. To the best of
our knowledge, these cases constitute the first report of
pathogenic IDH1 mutations in gastric cancer. Recently
IDH1 mutations have been targeted [33], and mutation-
specific treatments are currently the aim of a phase I
clinical trial that includes cholantiocarcinomas (http://
clinicaltrial.gov/ct2/show/NCT02073994). FLT3mutations
occur in a third of cases of acute myelogenous leukemia
[56], and the point mutation resulting in the A680V sub-
stitution has not been previously described in gastric can-
cer, while being observed occasionally in AML [57].
Similarly, activating JAK3 mutations such as V722I have
been identified in acute megakaryoblastic leukemia [58]
and NK/T-cell lymphoma [31], and only in a few cases of
gastric and breast cancer [59].Epidemiologic and clinicopathologic differences exist
between GEJ and gastric carcinomas [60-62]. GEJ carcin-
omas in this cohort were associated with younger age, dif-
ferent histotypes, and worse disease-free survival. As in
other series, the rates of p53 overexpression were higher
in the GEJ, as were the rates of TP53 mutation [10,11],
while Wnt abnormalities were more common in the gas-
tric carcinomas [12]. In addition, more frequently there
were mutations across ≥3 genes in gastric carcinomas,
suggesting a higher mutational load and/or a bias towards
genes included in the panel compared to GEJ lesions. Al-
though the absence of differences in actionable mutations
suggests that tumors in these sites can be considered to-
gether, the differences in TP53 and Wnt component mu-
tation rates support the recent push to use location to
distinguish proximal and distal gastric carcinomas as sep-
arate entities. Based on gene expression data, Shah et al.
recently suggested that gastric carcinomas be grouped
into three different subtypes [16]. The detection of more
frequent KRAS mutations within distal non-diffuse car-
cinomas in our dataset when using this subclassification
further supports pathologic classification of gastric can-
cers based on location and histotype.
Overall, mutation frequencies within the targeted hot-
spots were detected at a similar rate as those observed
with exome sequencing in the TCGA data, also suggest-
ing that with appropriate design, panel sequencing could
be a viable method for interrogating multiple genes with
a single test. Cases with mutations in ≥3 genes were also
more common in the stomach in this cohort. However, the
differences in mutation rates in TP53, KRAS, and APC/
CTNNB1 between GEJ and gastric carcinomas were not
observed within the TCGA cohort, even after comparing
mutation frequencies within specific gastric locations. It is
uncertain whether differences in case selection relating to
etiology, geography or ethnicity could account for such
differences, or whether differences in sequencing technol-
ogy or bioinformatic analyses may also have contributed
to these divergent observations. Further studies directly
comparing the two approaches and comparing different
patient populations will further enhance our understand-
ing of GEJ and gastric carcinoma.
Study limitations
Regarding case selection, in the presence of gastroesoph-
ageal reflux many of the landmarks used to delineate the
stomach from the esophagus are destroyed. This study
relied on the epicenter of the tumor being 5 cm from
the gastroesophageal junction. However, we derived this
classification from pathology reports and could not con-
firm the gross descriptions, nor did we subclassify tu-
mours by Siewert type. Many of the tumours in this
series may have in fact been esophageal in origin, and
this could explain the similarities of the tumours with
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rates of TP53 mutations). The patients’ family histories
were not recorded for correlation, and the presence of
gastric and GEJ cancer risk factors such as Helicobacter
infection and Barrett esophagus were also not recorded.
Sampling for sequencing and tissue microarray construc-
tion was limited, and intratumoral heterogeneity was not
addressed. No germline DNA was available for compari-
son; as a result some somatic variants, which contribute
to carcinogenesis but are present at low frequencies as
single nucleotide polymorphisms, may have been omitted.
In addition, we did not perform validation with Sanger se-
quencing or other methods. As such, we could not con-
firm the assay’s sensitivity and specificity on this series.
The assay has been shown to be accurate in other studies
and in our own laboratory. Further validation of this plat-
form with Sanger sequencing or other methods would be
required before this assay could be used clinically.
Conclusions
GEJ and gastric tumors differ in several clinicopathologic
respects, including the frequencies of mutations in cer-
tain caner-related genes. Tailoring treatment towards in-
dividual gastric cancer patients will require in-depth
characterization of their tumors. This study shows that
such characterization will derive information from both
traditional clinicopathologic parameters such as tumor
location, as well as from emerging molecular assays. Tar-
geted panel sequencing is an approach that can be applied
towards routine pathology material and can simultan-
eously yield information on several genes. Refinement of
this approach may be a powerful tool for pathologists and
clinicians in the future.Additional files
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